Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
FG New America Acquisition (FGNA.U)
Boqii Holding Limited (BQ)
Orphazyme A/S (ORPH)
Palantir Technologies Inc. (PLTR)
Yalla Group Limited (YALA)
Recharge Acquisition (RCHGU)
Chindata Group Holdings Limited (CD)
Asana, Inc. (ASAN)
Lixiang Education Holding Co., Ltd. (LXEH)
Pulmonx Corporation (LUNG)
Mission Produce, Inc. (AVO)
Academy Sports and Outdoors, Inc. (ASO)
Immunome Inc. (IMNM)
Priced IPO
Amesite Operating (AMST)
VIA optronics AG (VIAO)
Prelude Therapeutics Incorporated (PRLD)
Graybug Vision, Inc. (GRAY)
PMV Pharmaceuticals, Inc (PMVP)
Siyata Mobile Inc. (SYAT)
Taysha Gene Therapies, Inc. (TSHA)
Bentley Systems, Inc. (BSY)
Corsair Gaming, Inc. (CRSR)
GoodRx Holdings, Inc. (GDRX)
Laird Superfood, Inc. (LSF)
Unity Software, Inc. (U)
Vitru Limited (VTRU)
Athira Pharma, Inc. (ATHA)
COMPASS Pathways plc (CMPS)
Broadstone Net Lease Inc. (BNL)
Sumo Logic, Inc. (SUMO)
Pactiv Evergreen Inc (PTVE)
American Well Corporation (AMWL)
Dyne Therapeutics Inc (DYN)
More companies

Lyra Therapeutics, Inc. (LYRA)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases. Their proprietary technology platform, XTreo, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. Their initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS. The therapeutic embedded within LYR-210 and LYR-220 is mometasone furoate, which is the active ingredient in various U.S. Food and Drug Administration, or FDA, approved drugs and has a well-established efficacy and safety profile. CRS is an inflammatory disease of the paranasal sinuses which leads to debilitating symptoms and significant morbidities and affects approximately 14 million people in the United States. They are advancing LYR-210 as a preferred alternative to surgery in an ongoing Phase 2 LANTERN clinical trial for CRS patients who have failed medical management.
Industry
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
CEO CFO
Maria Palasis R. Don Elsey
Employees Founded
34 2005

Contacts

Address: 480 Arsenal Way, Watertown, MA 02472, US

Telephone: (617) 393-4600

Web page: http://www.lyratherapeutics.com

IPO information

Expected Date 5/1/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) -
Revenues (MM) $0
Net Income (Loss) (MM) $-16.3

Voting

What do you think will happen with the LYRA share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 3.5
Shares Revised (MM) 3.5
Expected offer amount (MM) $56
Realized offer amount(MM) $56
Underwriters
BofA Securities/ Jefferies/ William Blair
CO-Managers
BTIG

Sector: Healthcare

Tweets about $LYRA

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats